Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Withdrawn × Carcinoma, Renal Cell × Clear all

Phase

Phase 2 17 Phase NA 14 Phase 1/2 6 Phase 1 6 Phase 3 3 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Completed 4 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 6 Carcinoma, Hepatocellular 5 Head and Neck Neoplasms 4 Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Neoplasms, Squamous Cell 2 Glioblastoma 2 Colonic Neoplasms 2 Urinary Incontinence 1 Tuberous Sclerosis 1 Sarcoma 1 Recurrent respiratory papillomatosis 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Postoperative Complications 1 Papillomavirus Infections 1 Papilloma 1 Ovarian Neoplasms 1 Orgasm 1 Oligodendroglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Melanoma 1 Medication Adherence 1 Lymphoma, T-Cell, Peripheral 1

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07084909 2025-12-10

HARRIER

Lantheus Medical Imaging

Phase 2/3 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡